These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32696305)

  • 1. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience.
    Allen CJ; Blumenthaler AN; Smith GL; Das P; Minsky BD; Blum M; Ajani J; Mansfield PF; Ikoma N; Badgwell BD
    Ann Surg Oncol; 2021 Feb; 28(2):758-765. PubMed ID: 32696305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
    Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
    Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis.
    Mokdad AA; Yopp AC; Polanco PM; Mansour JC; Reznik SI; Heitjan DF; Choti MA; Minter RR; Wang SC; Porembka MR
    JAMA Oncol; 2018 Jan; 4(1):31-38. PubMed ID: 28975352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
    Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer.
    Kim DW; Lee G; Hong TS; Li G; Horick NK; Roeland E; Keane FK; Eyler C; Drapek LC; Ryan DP; Allen JN; Berger D; Parikh AR; Mullen JT; Klempner SJ; Clark JW; Wo JY
    Ann Surg Oncol; 2022 Jan; 29(1):242-252. PubMed ID: 34480285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer.
    Li R; Hou WH; Chao J; Woo Y; Glaser S; Amini A; Nelson RA; Chen YJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):950-958. PubMed ID: 30099371
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
    Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
    Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.
    Barrak D; Villano AM; Villafane-Ferriol N; Stockton LG; Hill MV; Deng M; Handorf EA; Reddy SS
    Eur J Surg Oncol; 2022 Jun; 48(6):1356-1361. PubMed ID: 35016837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis.
    Girardi DM; de Lima MA; Pereira GCB; Negrão MV; López RVM; Capareli FC; Sabbaga J; Hoff PMG
    BMC Cancer; 2018 Apr; 18(1):378. PubMed ID: 29614980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study.
    Stiekema J; Trip AK; Jansen EP; Aarts MJ; Boot H; Cats A; Ponz OB; Gradowska PL; Verheij M; van Sandick JW
    Ann Surg Oncol; 2015 Feb; 22(2):581-8. PubMed ID: 25164039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.
    Cloyd JM; Chen HC; Wang X; Tzeng CD; Kim MP; Aloia TA; Vauthey JN; Lee JE; Katz MHG
    Pancreas; 2019 Feb; 48(2):216-222. PubMed ID: 30629022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.